Tempest Therapeutics (NASDAQ:TPST) Receives Outperform Rating from William Blair

Tempest Therapeutics (NASDAQ:TPST)‘s stock had its “outperform” rating restated by stock analysts at William Blair in a research report issued on Wednesday,RTT News reports.

Separately, HC Wainwright restated a “buy” rating and set a $47.00 price target on shares of Tempest Therapeutics in a report on Wednesday. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Tempest Therapeutics currently has a consensus rating of “Buy” and an average price target of $20.75.

Tempest Therapeutics Stock Down 1.8 %

NASDAQ TPST opened at $1.08 on Wednesday. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.17 and a quick ratio of 2.17. The company’s 50 day simple moving average is $1.21 and its 200 day simple moving average is $1.98. Tempest Therapeutics has a 12 month low of $0.86 and a 12 month high of $6.00. The company has a market capitalization of $27.23 million, a P/E ratio of -0.67 and a beta of -1.78.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Fullcircle Wealth LLC acquired a new position in Tempest Therapeutics in the 3rd quarter valued at approximately $87,000. Empower Advisory Group LLC acquired a new position in shares of Tempest Therapeutics during the 3rd quarter worth $49,000. Virtu Financial LLC increased its stake in shares of Tempest Therapeutics by 69.2% during the 1st quarter. Virtu Financial LLC now owns 28,574 shares of the company’s stock worth $112,000 after purchasing an additional 11,689 shares during the last quarter. Finally, Dimensional Fund Advisors LP acquired a new position in shares of Tempest Therapeutics during the 2nd quarter worth $55,000. Institutional investors and hedge funds own 22.52% of the company’s stock.

About Tempest Therapeutics

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.